Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 17/20 | 0.59 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5690943 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4RAB9AHPGDFFAR1 | |
| SCHEMBL5692089 | 0.93 | ITGB1 (0.56) | ITGB1ITGA4RAB9A | |
| SCHEMBL5691018 | 0.93 | ITGB1 (0.56) | ITGB1ITGA4RAB9A | |
| SCHEMBL5690676 | 0.91 | ITGB1 (0.63) | ITGB1ITGA4HPGD | |
| SCHEMBL5692264 | 0.91 | ITGB1 (0.63) | ITGB1ITGA4HPGD | |
| SCHEMBL6160961 | 0.89 | ITGA4 (0.45) | ITGB1ITGA4RAB9AHPGD | |
| SCHEMBL5692320 | 0.88 | ITGA4 (0.61) | ITGB1ITGA4 | |
| SCHEMBL5692324 | 0.88 | ITGA4 (0.61) | ITGB1ITGA4 | |
| SCHEMBL5691258 | 0.82 | ITGA4 (0.53) | ITGB1ITGA4RAB9A | |
| SCHEMBL5691261 | 0.82 | ITGA4 (0.53) | ITGB1ITGA4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137782-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137782-A1 | Substituted bicyclic compounds | ITGA1, VCAM1, ITGB1 | ITGB1 3/4885ITGA4 4/4885RAB9A 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.